鲁索替尼乳膏(Opzelura)治疗白癜风的效果好不好？

Ruxolitinib cream (Opzelura) is effective in treating vitiligo and has significant curative effect. Clinical data showed that after 24 weeks of treatment with ruxolitinib cream, ruxolitinib cream was significantly better than placebo in improving the vitiligo severity index.

Ruxolitinib Cream

The U.S. Food and Drug Administration (FDA) has approved it as the first home treatment for non-segmental vitiligo. Non-segmental vitiligo is an autoimmune disease that causes spots and patches on the skin. Previously, it was used to treat atopic dermatitis, myelofibrosis, essential thrombocythemia, and polycythemia vera.

Ruxolitinib cream (Opzelura) works by reducing an individual's heightened immune response, gradually promoting the development of new, healthy skin cells, and ultimately reintroducing pigment to the affected area. Using this topical wash twice daily not only produces an even skin tone, it also improves patient confidence. Relatively more effective and has a better safety profile than the oral form of the drug.

Ruxolitinib cream (Opzelura) for the treatment of vitiligo

In a clinical study, at 24 weeks, 21% of patients improved by 75% after using 1.5g of ruxolitinib cream twice daily. To understand the long-term efficacy of ruxolitinib cream, the study extended treatment through week 52, and 52.6% of patients using ruxolitinib cream had a 75% or greater improvement in Facial Vitiligo Area Score Index (F-VASI) from baseline.

In the placebo group who switched to ruxolitinib cream, 7.4% of participants achieved F-VASI75 at 24 weeks and 26.8% achieved F-VASI75 at 52 weeks.

A total of 674 adult and pediatric subjects aged 12 years and older were enrolled in two identically designed, double-blind, randomized, vehicle-controlled trials and were randomized to receive ruxolitinib cream or vehicle cream twice daily (BID) for 24 weeks, followed by ruxolitinib cream BID for an additional 28 weeks.

Study 1 showed that 29.9% of the ruxolitinib cream group had an improvement of at least 75% and only 7.5% of the placebo group. In Study 2, 29.9% of the ruxolitinib cream group had an improvement of at least 75% and only 12.9% of the placebo group.

Study 1 showed that 15.5% of the ruxolitinib cream group had an improvement of at least 90% and only 2.2% of the placebo group. In Study 2, 15.4% of the ruxolitinib cream group had an improvement of at least 90% and only 1.9% of the placebo group.

Usage and Dosage

1. Non-segmental vitiligo: Apply a thin layer to the affected area up to 10% of the body surface area, 2 times a day.

2. Atopic dermatitis: Apply a thin layer to the affected area up to 20% of the body surface area, 2 times a day.

It should be noted that no more than one 60g tube should be used per week or one 100g tube every two weeks.

Medication

1. Serious infection: Serious bacterial, mycobacterial, fungal and viral infections have occurred. Monitor the patient's infection status regularly and deal with it in a timely manner.

2. Non-melanoma skin cancer: Perform regular skin examinations during and after treatment.

3. Thrombosis: Thromboembolic events have occurred, and signs should be monitored during medication.

4. Thrombocytopenia, anemia and neutropenia: CBC monitoring should be carried out according to clinical indications.

Price

The reference price of Yaopin International version of ruxolitinib cream for 30mg is about $559 per box.

Summary

Ruxolitinib cream has significant efficacy in the treatment of vitiligo, but it has some adverse reactions. Therefore, you need to carefully evaluate the risks and benefits and follow your doctor's advice when using this drug.

References: